Abstract:The androgen receptor (AR) is a modular transcription factor which functions as a master regulator of gene expression. AR protein is composed of three functional domains; the ligand-binding domain (LBD); DNA-binding domain (DBD); and the intrinsically disordered N-terminal transactivation domain (TAD). AR is transactivated upon binding to the male sex hormone testosterone and other androgens. While the AR may tolerate loss of its LBD, the TAD contains activation function-1 (AF-1) that is essential for all AR transcriptional activity. AR is frequently over-expressed in most prostate cancer. Currently, androgen deprivation therapy (ADT) in the form of surgical or chemical castration remains the standard of care for patients with high risk localized disease, advanced and metastatic disease, and those patients that experience biochemical relapse following definitive primary treatment. Patients with recurrent disease that receive ADT will ultimately progress to lethal metastatic castration-resistant prostate cancer. In addition to ADT not providing a cure, it is associated with numerous adverse effects including cardiovascular disease, osteoporosis and sexual dysfunction. Recently there has been a renewed interest in investigating the possibility of using antiandrogens which competitively bind the AR-LBD without ADT for patients with hormone sensitive, non-metastatic prostate cancer. Here we describe a class of compounds termed AR transactivation domain inhibitors (ARTADI) and their mechanism of action. These compounds bind to the AR-TAD to inhibit AR transcriptional activity in the absence and presence of androgens. Thus these inhibitors may have utility in preventing prostate cancer growth in the non-castrate setting.

Recent Androgen Receptor Antagonists in Prostate Cancer

Recent Developments in Androgen Receptor Antagonists.

Androgen receptor inhibitors in treating prostate cancer

Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer.

Identification of Novel Androgen Receptor Degrading Agents to Treat Advanced Prostate Cancer

Degradation of Androgen Receptor Through Small Molecules for Prostate Cancer

A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives

Advances in the computational development of androgen receptor antagonists

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

Research Progress on Non-Steroidal Androgen Receptor Antagonists

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

PROTACs Targeting Androgen Receptor Signaling: Potential Therapeutic Agents for Castration-Resistant Prostate Cancer

Research progress on prostate cancer drugs targeting different sites of androgen receptor

Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

The Androgen Receptor and Its Crosstalk with the Src Kinase During Castrate-Resistant Prostate Cancer Progression

Androgen Receptor Roles in Benign and Malignant Prostate Disease

Androgen receptor modulators: a review of recent patents and reports (2012-2018)

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer